Studies conducted using the H596 NSCLC xenograft model have indicated that combining ficlatuzumab with epidermal growth factor receptor (EGFR) inhibitors such as erlotinib or cetuximab enhances its anti-cancer effects compared to using either agent alone. The gene discussed is EGFR; the disease is cancer.